DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AIN457 is an investigational drug.
There have been 51 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.
The most common disease conditions in clinical trials are Arthritis, Psoriasis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.
There are two US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for AIN457
|Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis||Novartis Pharmaceuticals||Phase 3|
|Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa||Novartis Pharmaceuticals||Phase 3|
|Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis||Novartis Pharmaceuticals||Phase 3|
Top disease conditions for AIN457
Top clinical trial sponsors for AIN457
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AIN457||Start Trial||Substituted pyrimidinone-phenyl-pyrimidinyl compounds||CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)||Start Trial|
|AIN457||Start Trial||Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients||Corning Incorporated (Corning, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AIN457||World Intellectual Property Organization (WIPO)||2013086208||2031-12-06||Start Trial|
|AIN457||European Patent Office||2796429||2033-04-24||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|